Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

NYU Clinical Cancer Center, New York

Memorial Sloan Kettering Cancer Center, New York

University of Pennsylvania, Philadelphia

Fairfax Northern Virginia Hematology Oncology, Fairfax

Duke University Medical Center, Durham

Cancer Centers of the Carolinas, ITOR, Greenville

Medical College of Georgia, Augusta

Mount Sinai Comprehensive Cancer Center, Miami Beach

Florida Cancer Specialists, Fort Myers

Sarah Cannon Research Institute, Nashville

Ohio State University GYN Oncology, Hilliard

Central Indiana Cancer Centers, Indianapolis

University of Michigan Health System, Ann Arbor

Wayne State University, Detroit

Midwest Hematology Oncology Consultants, St Louis

Kansas City Cancer Center, Lee's Summit

University of Missouri Health Care, Columbia

Tulane University Health Sciences Center, New Orleans

University of Oklahoma, Oklahoma City

Cancer Care Associates, Tulsa

Mary Crowley Medical Research Center, Dallas

Tyler Cancer Center, Tyler

University of Texas, M. D., Anderson Cancer Center, Houston

Texas Oncology - Central Austin Cancer Center, Austin

Rocky Mountain Cancer Centers, Denver

Pinnacle Oncology of Arizona, Scottsdale

Comprehensive Cancer Centers of Nevada, Las Vegas

University of California, San Francisco, San Francisco

Stanford University Medical Center, Stanford

University of California Davis Cancer Center, Sacramento

Northwest Cancer Specialists, Tualatin

University of Washington, Seattle

Yale University School of Medicine, New Haven

Dana Farber Cancer Center, Boston

One Study Location, Brussels

One Study Location, Jette

Multiple Study Locations, Leuven

Liège

One Study Location, Mons

One Study Location, Jerusalem

One Study Location, Tel Aviv

One Study Location, Tel Litwinsky

One Study Location, Ẕerifin

Multiple Study Locations, Tainan City

Chang Gung Medical Foundation, Taoyuan County, Taipei

Taipei

One Study Location, London